Skip to content
MTLS

Materialise N.V.

Materialise N.V. Q3 FY2025 earnings call

October 28, 2025 · fiscal period ended 2025-10

EPS · actual vs est

/

Revenue · actual vs est

/
Ask about this call

Summary

Generated 2025-10-28

Management highlights

Management Statement and Operational Highlights

  • Medical: Achieved double-digit growth, acquired FEops for cardiac simulation, released new versions of planners with clinical evidence showing time savings in procedures, and progress in existing markets like trauma with new Mimics Enlight CMF planner.
  • Software: Continued progress on CO-AM ecosystem, launched Magics SDKs and next-generation build processors, and introduced low-code enabling technology on CO-AM to make SDKs more accessible.
  • Manufacturing: Invested in large/high-complexity parts, made progress in defense sector, leveraging additive manufacturing for defense industry benefits such as rapid and sustainable production.
View in transcript ↓

Segment performance

Segment Performance

  • Medical: Posted an all-time revenue record of EUR 33.3 million in Q3 2025, growing over 10% compared to Q3 2024, contributing 50% of total revenue. Year-to-date, revenue was EUR 97.2 million, up 15%, with adjusted EBITDA of EUR 30 million (31% margin).
  • Software: Revenue decreased by 7% to EUR 10.3 million in Q3 2025, contributing 16% of total revenue. Year-to-date, revenue was EUR 30 million, with adjusted EBITDA of EUR 3.8 million.
  • Manufacturing: Revenue declined by 17% to EUR 22.7 million in Q3 2025, contributing 34% of total revenue. Year-to-date, revenue was EUR 70.3 million, with adjusted EBITDA negative EUR 2 million.
View in transcript ↓

Guidance

Guidance

  • Maintained full-year 2025 guidance with revenues in the range of EUR 265 million to EUR 280 million and adjusted EBIT in the range of EUR 6 million to EUR 10 million.
View in transcript ↓

Risks

Risks

  • General market uncertainties, competitive dynamics, and macroeconomic headwinds impacting Software and Manufacturing segments.
View in transcript ↓

Q&A highlights

Question and Answer Q: Could you rank order Medical segments and discuss growth potential of cardiac and other new markets?

A: Existing markets like CMF and orthopedics are more mature, new markets like cardiac and respiratory are smaller but expected to grow faster. The majority of revenue comes from existing markets, but new markets show potential.

Q: How big is aerospace and defense as a percentage of revenue in Manufacturing, and details on materials?

A: Aerospace is a focus segment with polymer applications in interiors and tooling. Defense involves a combination of polymer and metal, with examples like Airbus qualification in polymer.

Q: Thoughts on Manufacturing profitability and recovery drivers?

A: Cost reduction measures implemented, but recovery relies on European industrial market recovery and automotive industry recovery to boost revenue.

View in transcript ↓

Key numbers

Reported versus consensus

Earnings calendar feed

MetricReportedConsensusDeltaPrior year
EPS
Revenue

Transcript

October 28, 2025

Full transcript unavailable for redistribution

The structured summary above covers the available call sections. Full transcript text is not included on this page.

Continue exploring

Prior quarters

This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.